ABT Q4 2016 Earnings Report — Abbott Laboratories Revenue & Financial Results | Market Cap Arena

Abbott LaboratoriesABT

Q4 2016 Earnings

Reported February 17, 2017

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	Q4 2016	Q3 2016	Q4 2015	QoQ Change	YoY Change
Revenue	$5.3B	$5.3B	—	0.6%	—
Op. Income	$975M	$918M	—	6.2%	—
Gross Margin	54.7%	54.2%	—	0.5pp	—
Net Margin	15.0%	-6.2%	—	21.2pp	—
EPS (Diluted)	$0.54	$-0.22	—	345.5%	—
Free Cash Flow	$851M	$905M	—	-6.0%	—

Revenue Flow

Item	Amount
REVENUE	$5.3B
Cost of Revenue	$2.4B
GROSS PROFIT	$2.9B
R&D Expenses	$338M
Selling & Marketing	$0
General & Administrative	$1.6B
SG&A Expenses	$1.6B
Other Expenses	$0
Operating Expenses	$1.9B
Cost & Expenses	$4.4B
OPERATING INCOME	$975M
Interest Income	$24M
Interest Expense	$0
Other Income/Expenses	-$100M
INCOME BEFORE TAX	$875M
Income Tax Expense	$110M
Net Income from Continuing Ops	$765M
Net Income from Discontinued Ops	$33M
Other Adjustments	$0
NET INCOME	$798M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$798M
D&A	$319M
EBIT	$806M
EBITDA	$1.1B
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$5.3B
Cost of Revenue	$2.4B
GROSS PROFIT	$2.9B
R&D Expenses	$338M
Selling & Marketing	$0
General & Administrative	$1.6B
SG&A Expenses	$1.6B
Other Expenses	$0
Operating Expenses	$1.9B
Cost & Expenses	$4.4B
OPERATING INCOME	$975M
Interest Income	$24M
Interest Expense	$0
Other Income/Expenses	-$100M
INCOME BEFORE TAX	$875M
Income Tax Expense	$110M
Net Income from Continuing Ops	$765M
Net Income from Discontinued Ops	$33M
Other Adjustments	$0
NET INCOME	$798M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$798M
D&A	$319M
EBIT	$806M
EBITDA	$1.1B
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$798M
Depreciation & Amortization	$319M
Stock-Based Compensation	$47M
Deferred Income Tax	$248M
Other Non-Cash Items	$1.0B
Change in Working Capital	-$1.2B
OPERATING CASH FLOW	$1.2B
Capital Expenditure	-$319M
Acquisitions (Net)	-$7M
Purchases of Investments	-$1.8B
Sales/Maturities of Investments	$3.7B
Other Investing Activities	$8M
NET CASH FROM INVESTING	$1.6B
Net Debt Issuance	$13.8B
Common Stock Repurchased	$0
Common Dividends Paid	-$386M
Other Financing Activities	$42M
NET CASH FROM FINANCING	$13.5B
FREE CASH FLOW	$851M
Net Change in Cash	$16.1B

Balance Sheet

Item	Amount
Cash & Equivalents	$18.6B
Short-Term Investments	$155M
Net Receivables	$3.2B
Inventory	$2.4B
Other Current Assets	$2.3B
TOTAL CURRENT ASSETS	$26.8B
PP&E (Net)	$5.7B
Goodwill	$7.7B
Intangible Assets	$4.5B
Long-Term Investments	$2.9B
Tax Assets	$4.0B
Other Non-Current Assets	$3.3B
TOTAL NON-CURRENT ASSETS	$28.2B
TOTAL ASSETS	$55.0B
Account Payables	$1.2B
Short-Term Debt	$1.3B
Deferred Revenue	$0
Other Current Liabilities	$3.2B
TOTAL CURRENT LIABILITIES	$6.7B
Long-Term Debt	$20.7B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$2.7B
Other Non-Current Liabilities	$4.3B
TOTAL NON-CURRENT LIABILITIES	$27.6B
TOTAL LIABILITIES	$31.9B
Common Stock	$13.0B
Additional Paid-In Capital	$13.0B
Retained Earnings	$25.6B
Treasury Stock	-$10.8B
Accum. Other Comp. Income	-$7.3B
Other Equity	-$13.0B
TOTAL STOCKHOLDERS' EQUITY	$20.5B
Minority Interest	$179M
TOTAL EQUITY	$20.7B
TOTAL LIABILITIES & EQUITY	$55.0B
Total Debt	$22.0B
Net Debt	$3.4B